Clozaril superiority claim?
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will review Novartis'Clozaril (clozapine) for treatment of suicidality in patients with schizophrenia or schizoaffective disorders Nov. 4. The review will focus on a head-to-head study versus Lilly's Zyprexa (olanzapine). The meeting will take place at the Holiday Inn, Gaithersburg, Md. [To sign up for a webcast of this meeting, visit 1FDAAdvisoryCommittee.com.]...
You may also be interested in...
Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.
India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
QUOTED. 5 March 2021. Dedi Gilad.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: